A 12-week, randomized, subject and investigator blind, placebo-controlled trial to evaluate the effect of CP-866,087 on weight loss in obese, otherwise healthy adult subjects

Trial Profile

A 12-week, randomized, subject and investigator blind, placebo-controlled trial to evaluate the effect of CP-866,087 on weight loss in obese, otherwise healthy adult subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2008

At a glance

  • Drugs CP 866087 (Primary)
  • Indications Obesity
  • Focus Biomarker; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Oct 2008 Actual patient number (94) added as reported by ClinicalTrials.gov.
    • 19 Feb 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top